Evidence map›Paper›PMID 35359873›Full record

ArticleFrontiers in pharmacology2022

CD44/Folate Dual Targeting Receptor Reductive Response PLGA-Based Micelles for Cancer Therapy.

Ru Zhang, Yunying Jiang, Linkun Hao, Yang Yang, Ying Gao, Ningning Zhang, Xuecheng Zhang, Yimin Song

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 24 citations in OpenAlex.

  1. FeRSC advances · 2026
    Article
  2. Review
  3. Article
  4. The Hidden Power of Black Pepper: Exploring Piperine's Role in Cancer.Plant foods for human nutrition (Dordrecht, Netherlands) · 2025
    Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Ru ZhangPharmaceutical Engineering Laboratory, Department of Pharmaceutical Engineering, Qingdao University of Science and Technology, Qingdao, China.
Yunying JiangPharmaceutical Engineering Laboratory, Department of Pharmaceutical Engineering, Qingdao University of Science and Technology, Qingdao, China.
Linkun HaoPharmaceutical Engineering Laboratory, Department of Pharmaceutical Engineering, Qingdao University of Science and Technology, Qingdao, China.
Yang YangPharmaceutical Engineering Laboratory, Department of Pharmaceutical Engineering, Qingdao University of Science and Technology, Qingdao, China.
Ying GaoPharmaceutical Engineering Laboratory, Department of Pharmaceutical Engineering, Qingdao University of Science and Technology, Qingdao, China.
Ningning ZhangPharmaceutical Engineering Laboratory, Department of Pharmaceutical Engineering, Qingdao University of Science and Technology, Qingdao, China.
Xuecheng ZhangPharmaceutical Engineering Laboratory, Colloge of Marines Life Science, Ocean University of China, Qingdao, China.
Yimin SongPharmaceutical Engineering Laboratory, Department of Pharmaceutical Engineering, Qingdao University of Science and Technology, Qingdao, China.
Qingdao University of Science and Technology · CNOcean University of China · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study, a novel poly (lactic-co-glycolic acid) (PLGA)-based micelle was synthesized, which could improve the therapeutic effect of the antitumor drug doxorubicin hydrochloride (DOX) and reduce its toxic and side effects. The efficient delivery of DOX was achieved by active targeting mediated by double receptors and stimulating the reduction potential in tumor cells. FA-HA-SS-PLGA polymer was synthesized by amidation reaction, and then DOX-loaded micelles were prepared by dialysis method. The corresponding surface method was used to optimize the experimental design. DOX/FA-HA-SS-PLGA micelles with high drug loading rate and encapsulation efficiency were prepared. The results of hydrophilic experiment, critical micelle concentration determination, and hemolysis test all showed that DOX/FA-HA-SS-PLGA micelles had good physicochemical properties and biocompatibility. In addition, both

Indexed as

antitumordoxorubicin hydrochloride (DOX)dual targetmicellesreduction sensitivetumor actively targeted

Identifiers

PMID35359873
PMCPMC8960309
OpenAlexW4220833269

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.